Table 3

Mortality HRs for psychotropic drugs in the total study sample

Basic Cox model*Cox model with interactions*
HRSDp ValueHRSDp Value
Age1.1020.001<0.0011.1020.001<0.001
Gender (female)0.7340.012<0.0010.7340.012<0.001
Control group0.6000.013<0.0010.5470.015<0.001
Charlson comorbidity index1.1750.010<0.0011.1690.010<0.001
SSRI (incl. SNRI)1.7370.014<0.0011.2700.029<0.001
TCA1.5000.036<0.0011.4040.045<0.001
BZD1.7200.032<0.0011.5320.023<0.001
BZD-like drugs1.5360.027<0.0011.3400.021<0.001
FGA2.3740.057<0.0012.2600.076<0.001
SGA1.9340.054<0.0011.7450.070<0.001
Interactions
 Control×SSRI1.1650.045<0.001
 Control×TCA1.2090.0750.011
 Control×BZD1.1640.0570.143
 Control×BZD-like drugs1.2360.032<0.001
 Control×FGA1.1250.1150.305
 Control×SGA1.3270.1110.011
Observations136 068136 068
Per cent censored75.175.1
  • Bold typeface indicates p<0.001.

  • Time-varying covariates were calculated in year 2, when all time-dependent covariates were significant in the time test.

  • Estimate=a+a_t×year.

  • *Time interaction coefficient not reported.

  • BZD, benzodiazepine; FGA, first-generation antipsychotic; SGA, second-generation antipsychotic; SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.